Intellia Thera CS (NTLA)

$13.37 +0.28 (2.14%)
Market Cap 2.00B
Revenue (ttm) 67.67M
Net Income (ttm) -412.69M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -609.86%
Debt to Equity Ratio 0.00
Volume 8,527,243
Avg Vol 5,354,138
Day's Range N/A - N/A
Shares Out 139.72M
Stochastic %K 7%
Beta 1.93
Analysts Sell
Price Target $25.80

Company Profile

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-20...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 285 6200
Address:
40 Erie Street, Suite 130, Cambridge, United States
Still_a_Chance
Still_a_Chance May. 15 at 5:37 PM
$NTLA seems like there will be incoming news 👌
0 · Reply
cdewder
cdewder May. 15 at 4:04 PM
$NTLA The swings on this are wild!
0 · Reply
jewell69
jewell69 May. 15 at 2:59 PM
1498.25 pure profit $NTLA Folks, don't try this at home. It almost wasn't worth it (worrying about it.) ditto our gains in $ONDS 05/15/2026 Sell Edit cost basis method NTLA INTELLIA THERAPEUTICS IN 450 $13.8601 $0.22 $6,236.83 More 05/14/2026 Buy NTLA INTELLIA THERAPEUTICS IN 450 $13.18 -$5,931.00 More 04/30/2026 Sell NTLA INTELLIA THERAPEUTICS IN 500 $13.4121 $0.24 $6,705.81 More 04/29/2026 Buy NTLA INTELLIA THERAPEUTICS IN 500 $12.30 -$6,150.00 More 04/28/2026 Sell NTLA INTELLIA THERAPEUTICS IN 500 $13.10 $0.23 $6,549.77 More 04/27/2026 Buy NTLA INTELLIA THERAPEUTICS IN 500 $12.7808 -$6,390.40 More 04/24/2026 Sell NTLA INTELLIA THERAPEUTICS IN 500 $15.16 $0.26 $7,579.74 More 04/24/2026 Buy NTLA INTELLIA THERAPEUTICS IN 500 $14.96 -$7,480.00 More 04/17/2026 Sell NTLA INTELLIA THERAPEUTICS IN 500 $14.8355 $0.25 $7,417.50 More 04/16/2026 Buy NTLA INTELLIA THERAPEUTICS IN 500 $14.08 -$7,040.00 More Total $1.20 $1,498.25
1 · Reply
APman
APman May. 15 at 1:35 PM
$NTLA Panic!
0 · Reply
APman
APman May. 15 at 1:28 PM
$NTLA
1 · Reply
jewell69
jewell69 May. 15 at 1:06 PM
Not sure if this is going to do any great shakes but SpaceX could drop their prospectus next week (5/19/26) but $RONB is about 7.3% SpaceX Looking for a rebound in $NTLA we b yesterday 13.18; close was about 13.03 yesterday. “Europe is getting killed” FNORX out performs all of Europe $FEZ $IEV I might look at $EUFN
1 · Reply
Newcar
Newcar May. 15 at 12:33 PM
$NTLA Come on! Bring it down...I want to buy it for $12
0 · Reply
hichemben
hichemben May. 15 at 11:29 AM
$NTLA It's clear the floor is $12, and I think Cathie will step in again to load today! Possibly, the last time we get the discounted price and we can get before the reveal to $17+🚀🔥 Let's goooo💎
1 · Reply
Newcar
Newcar May. 15 at 8:31 AM
$NTLA under 13$ is a good chance to invest. 12$ next week?
0 · Reply
Newcar
Newcar May. 15 at 8:29 AM
$NTLA Is Cathie Wood a real good investor or a loser?🤔😅
1 · Reply
Latest News on NTLA
Intellia Therapeutics price target raised to $17 from $13 at Bernstein

2026-05-13T10:34:18.000Z - 2 days ago

Intellia Therapeutics price target raised to $17 from $13 at Bernstein

Intellia Therapeutics price target lowered to $25 from $30 at H.C. Wainwright

2026-05-13T10:28:35.000Z - 2 days ago

Intellia Therapeutics price target lowered to $25 from $30 at H.C. Wainwright

Intellia Therapeutics Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 6:40 PM EDT - 2 days ago

Intellia Therapeutics Transcript: Bank of America Global Healthcare Conference 2026

Intellia Therapeutics price target lowered to $19 from $20 at BofA

2026-05-12T16:07:18.000Z - 3 days ago

Intellia Therapeutics price target lowered to $19 from $20 at BofA

Intellia Therapeutics price target lowered to $49 from $58 at Canaccord

2026-05-12T11:12:55.000Z - 3 days ago

Intellia Therapeutics price target lowered to $49 from $58 at Canaccord

Intellia Therapeutics reports Q1 EPS (81c), consensus (90c)

2026-05-11T17:26:11.000Z - 4 days ago

Intellia Therapeutics reports Q1 EPS (81c), consensus (90c)

Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

May 11, 2026, 7:30 AM EDT - 4 days ago

Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

Intellia Therapeutics to Participate in Upcoming Investor Conferences

May 5, 2026, 7:30 AM EDT - 10 days ago

Intellia Therapeutics to Participate in Upcoming Investor Conferences

Cathie Wood’s ARK Investment buys 141K shares of Intellia Therapeutics today

2026-05-02T00:11:02.000Z - 13 days ago

Cathie Wood’s ARK Investment buys 141K shares of Intellia Therapeutics today

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 1, 2026, 4:01 PM EDT - 13 days ago

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cathie Wood’s ARK Investment buys 2.4M shares of Intellia Therapeutics today

2026-04-30T03:26:02.000Z - 15 days ago

Cathie Wood’s ARK Investment buys 2.4M shares of Intellia Therapeutics today

Unusually active option classes on open April 29th

2026-04-29T16:37:10.000Z - 16 days ago

Unusually active option classes on open April 29th

BBAI CVNA CVS FCEL JOBY PLUG QCOM

Intellia Therapeutics 16.7M share Secondary priced at $10.75

2026-04-29T15:02:56.000Z - 16 days ago

Intellia Therapeutics 16.7M share Secondary priced at $10.75

Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

Apr 29, 2026, 7:00 AM EDT - 16 days ago

Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

Cathie Wood’s ARK Investment buys 596K shares of Intellia Therapeutics today

2026-04-29T00:13:03.000Z - 16 days ago

Cathie Wood’s ARK Investment buys 596K shares of Intellia Therapeutics today

Cathie Wood Offloads Rocket Lab Stock (RKLB) Despite 3% Jump, Buys the Dip in Intellia (NTLA)

2026-04-28T13:00:00.000Z - 17 days ago

Cathie Wood Offloads Rocket Lab Stock (RKLB) Despite 3% Jump, Buys the Dip in Intellia (NTLA)

ARKG ARKK ARKQ RKLB

Intellia Therapeutics price target raised to $13 from $7 at Baird

2026-04-28T11:21:47.000Z - 17 days ago

Intellia Therapeutics price target raised to $13 from $7 at Baird

Intellia Therapeutics price target raised to $58 from $48 at Canaccord

2026-04-28T11:12:55.000Z - 17 days ago

Intellia Therapeutics price target raised to $58 from $48 at Canaccord

Intellia Therapeutics price target raised to $9 from $8 at Goldman Sachs

2026-04-28T10:29:23.000Z - 17 days ago

Intellia Therapeutics price target raised to $9 from $8 at Goldman Sachs

Intellia Therapeutics price target raised to $30 from $28 at Citizens

2026-04-28T09:45:14.000Z - 17 days ago

Intellia Therapeutics price target raised to $30 from $28 at Citizens

Cathie Wood’s ARK Investment buys 264K shares of Intellia Therapeutics today

2026-04-28T00:10:21.000Z - 17 days ago

Cathie Wood’s ARK Investment buys 264K shares of Intellia Therapeutics today

Intellia Therapeutics announces $150M common stock offering

2026-04-27T20:06:44.000Z - 17 days ago

Intellia Therapeutics announces $150M common stock offering

Intellia Announces Proposed Public Offering of Common Stock

Apr 27, 2026, 4:01 PM EDT - 17 days ago

Intellia Announces Proposed Public Offering of Common Stock

Intellia Therapeutics price target raised to $30 from $27 at Chardan

2026-04-27T18:00:53.000Z - 18 days ago

Intellia Therapeutics price target raised to $30 from $27 at Chardan

Intellia Therapeutics Transcript: Study result

Apr 27, 2026, 8:00 AM EDT - 18 days ago

Intellia Therapeutics Transcript: Study result

Intellia Therapeutics' rare genetic disorder therapy meets main goal in trial

Apr 27, 2026, 7:06 AM EDT - 18 days ago

Intellia Therapeutics' rare genetic disorder therapy meets main goal in trial

Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial

Apr 27, 2026, 7:01 AM EDT - 18 days ago

Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial

Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema

Apr 27, 2026, 7:00 AM EDT - 18 days ago

Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema

Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing

Apr 27, 2026, 7:00 AM EDT - 18 days ago

Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing

Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026

Apr 24, 2026, 4:05 PM EDT - 20 days ago

Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026

Intellia Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 8:40 AM EDT - 2 months ago

Intellia Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Intellia Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 1:10 PM EST - 2 months ago

Intellia Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026

Mar 3, 2026, 7:30 AM EST - 2 months ago

Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026

US FDA lifts clinical hold on Intellia's heart disease gene therapy trial

Mar 2, 2026, 7:40 AM EST - 2 months ago

US FDA lifts clinical hold on Intellia's heart disease gene therapy trial

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM

Mar 2, 2026, 7:30 AM EST - 2 months ago

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM

Intellia Therapeutics Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:00 AM EST - 2 months ago

Intellia Therapeutics Earnings Call Transcript: Q4 2025

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

Feb 26, 2026, 7:30 AM EST - 2 months ago

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

Feb 19, 2026, 7:30 AM EST - 3 months ago

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

US FDA lifts clinical hold on Intellia's nerve disease trail

Jan 27, 2026, 8:13 AM EST - 3 months ago

US FDA lifts clinical hold on Intellia's nerve disease trail

Intellia Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 12:00 PM EST - 4 months ago

Intellia Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 7, 2026, 7:30 AM EST - 4 months ago

Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Nov 10, 2025, 3:17 PM EST - 6 months ago

Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Nov 8, 2025, 5:13 PM EST - 6 months ago

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

US FDA places clinical hold on Intellia's two gene-editing treatment trials

Oct 29, 2025, 5:11 PM EDT - 7 months ago

US FDA places clinical hold on Intellia's two gene-editing treatment trials

Intellia Therapeutics Transcript: Study Update

Oct 27, 2025, 8:30 AM EDT - 7 months ago

Intellia Therapeutics Transcript: Study Update

Intellia pauses late-stage trials of gene-editing treatment after serious liver event

Oct 27, 2025, 7:38 AM EDT - 7 months ago

Intellia pauses late-stage trials of gene-editing treatment after serious liver event

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)

Oct 27, 2025, 7:30 AM EDT - 7 months ago

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Sep 25, 2025, 9:52 AM EDT - 8 months ago

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema

Sep 18, 2025, 7:30 AM EDT - 8 months ago

Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema

Why big players are pouring millions in THIS biotech stock

Sep 1, 2025, 8:43 AM EDT - 9 months ago

Why big players are pouring millions in THIS biotech stock

Intellia Therapeutics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 10 months ago

Intellia Therapeutics Earnings Call Transcript: Q2 2025

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Aug 1, 2025, 7:30 AM EDT - 10 months ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates

Jul 31, 2025, 7:30 AM EDT - 10 months ago

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

Jun 15, 2025, 10:45 AM EDT - 11 months ago

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

Intellia Therapeutics Transcript: AGM 2025

Jun 11, 2025, 9:00 AM EDT - 1 year ago

Intellia Therapeutics Transcript: AGM 2025

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting

May 18, 2025, 7:25 AM EDT - 1 year ago

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting

Intellia Therapeutics Transcript: BofA Securities 2025 Healthcare Conference

May 13, 2025, 7:20 PM EDT - 1 year ago

Intellia Therapeutics Transcript: BofA Securities 2025 Healthcare Conference

Intellia Therapeutics Earnings Call Transcript: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Intellia Therapeutics Earnings Call Transcript: Q1 2025

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

May 1, 2025, 7:30 AM EDT - 1 year ago

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation

Apr 23, 2025, 9:50 AM EDT - 1 year ago

Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation

Final Deadline Today for the Intellia Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - NTLA

Apr 14, 2025, 10:58 AM EDT - 1 year ago

Final Deadline Today for the Intellia Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - NTLA

Still_a_Chance
Still_a_Chance May. 15 at 5:37 PM
$NTLA seems like there will be incoming news 👌
0 · Reply
cdewder
cdewder May. 15 at 4:04 PM
$NTLA The swings on this are wild!
0 · Reply
jewell69
jewell69 May. 15 at 2:59 PM
1498.25 pure profit $NTLA Folks, don't try this at home. It almost wasn't worth it (worrying about it.) ditto our gains in $ONDS 05/15/2026 Sell Edit cost basis method NTLA INTELLIA THERAPEUTICS IN 450 $13.8601 $0.22 $6,236.83 More 05/14/2026 Buy NTLA INTELLIA THERAPEUTICS IN 450 $13.18 -$5,931.00 More 04/30/2026 Sell NTLA INTELLIA THERAPEUTICS IN 500 $13.4121 $0.24 $6,705.81 More 04/29/2026 Buy NTLA INTELLIA THERAPEUTICS IN 500 $12.30 -$6,150.00 More 04/28/2026 Sell NTLA INTELLIA THERAPEUTICS IN 500 $13.10 $0.23 $6,549.77 More 04/27/2026 Buy NTLA INTELLIA THERAPEUTICS IN 500 $12.7808 -$6,390.40 More 04/24/2026 Sell NTLA INTELLIA THERAPEUTICS IN 500 $15.16 $0.26 $7,579.74 More 04/24/2026 Buy NTLA INTELLIA THERAPEUTICS IN 500 $14.96 -$7,480.00 More 04/17/2026 Sell NTLA INTELLIA THERAPEUTICS IN 500 $14.8355 $0.25 $7,417.50 More 04/16/2026 Buy NTLA INTELLIA THERAPEUTICS IN 500 $14.08 -$7,040.00 More Total $1.20 $1,498.25
1 · Reply
APman
APman May. 15 at 1:35 PM
$NTLA Panic!
0 · Reply
APman
APman May. 15 at 1:28 PM
$NTLA
1 · Reply
jewell69
jewell69 May. 15 at 1:06 PM
Not sure if this is going to do any great shakes but SpaceX could drop their prospectus next week (5/19/26) but $RONB is about 7.3% SpaceX Looking for a rebound in $NTLA we b yesterday 13.18; close was about 13.03 yesterday. “Europe is getting killed” FNORX out performs all of Europe $FEZ $IEV I might look at $EUFN
1 · Reply
Newcar
Newcar May. 15 at 12:33 PM
$NTLA Come on! Bring it down...I want to buy it for $12
0 · Reply
hichemben
hichemben May. 15 at 11:29 AM
$NTLA It's clear the floor is $12, and I think Cathie will step in again to load today! Possibly, the last time we get the discounted price and we can get before the reveal to $17+🚀🔥 Let's goooo💎
1 · Reply
Newcar
Newcar May. 15 at 8:31 AM
$NTLA under 13$ is a good chance to invest. 12$ next week?
0 · Reply
Newcar
Newcar May. 15 at 8:29 AM
$NTLA Is Cathie Wood a real good investor or a loser?🤔😅
1 · Reply
udim
udim May. 15 at 7:09 AM
$NTLA
0 · Reply
TheWolfOfWaterdown
TheWolfOfWaterdown May. 15 at 12:44 AM
$NTLA 14million volume today and I just noticed our short interest is up to 43M from 38M. Guess the big guys didn’t like the phase 3 results. Regardless I grabbed more today…
1 · Reply
ianleung
ianleung May. 15 at 12:02 AM
$NTLA ARK has almost 16M shares... this is nuts..
2 · Reply
noobinvestor1
noobinvestor1 May. 14 at 9:27 PM
$NTLA wth did I miss?
0 · Reply
hormany
hormany May. 14 at 9:14 PM
$NTLA wtf
0 · Reply
Abetwit
Abetwit May. 14 at 9:09 PM
$NTLA Max pain should be 14. Am I reading things wrong?
1 · Reply
GoodTidings
GoodTidings May. 14 at 8:27 PM
$NTLA $13 is option expiration max pain... So we'll probably float around that PPS tomorrow... 🤔🤔🤔
0 · Reply
GoodTidings
GoodTidings May. 14 at 8:24 PM
$NTLA
0 · Reply
GoodTidings
GoodTidings May. 14 at 8:21 PM
$NTLA So its all temporary price manipulation so MM can put money in their pockets of all uncovered written call options... 🤔🤔🤔
0 · Reply
GoodTidings
GoodTidings May. 14 at 8:19 PM
$NTLA With today's price manipulation by MM 6500 call contracts expire worthless... That is 650000 shares don't have to get delivered if pps remains below $13... 🤔🤔🤔
1 · Reply
Picklez_
Picklez_ May. 14 at 8:06 PM
$NTLA If it doesn't hold they bring it down to 4% higher than the last low which was 12.45, 12.45 x 1.04 = 12.95, I always hope for better but it's the same damn pattern.
0 · Reply
GoodTidings
GoodTidings May. 14 at 8:02 PM
$NTLA Option expiration manipulation... 🤔🤔🤔
0 · Reply